Sviss - ítalska - Swissmedic (Swiss Agency for Therapeutic Products)

meda pharma gmbh - mitoxantronum - concentrato per soluzione per infusione - mitoxantronum 10 mg ut mitoxantroni hydrochloridum, natrii chloridum, natrii sulfas, natrii acetas, acidum aceticum glaciale, aqua ad iniectabile q.s. ad solutionem pro 5 ml corresp. natrium 16.05 mg. - farmaco - synthetika

Sviss - ítalska - Swissmedic (Swiss Agency for Therapeutic Products)

meda pharma gmbh - mitoxantronum - concentrato per soluzione per infusione - mitoxantronum 20 mg ut mitoxantroni hydrochloridum, natrii chloridum, natrii sulfas, natrii acetas, acidum aceticum glaciale, aqua ad iniectabile q.s. ad solutionem pro 10 ml corresp. natrium 32.1 mg. - farmaco - synthetika

Ítalía - ítalska - AIFA (Agenzia Italiana del Farmaco)

meda pharma s.p.a. - mitoxantrone - mitoxantrone

Sviss - ítalska - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - ofatumumabum - soluzione iniettabile in siringa preriempita - ofatumumabum 20 mg, argininum, natrii acetas trihydricus, natrii chloridum, polysorbatum 80, dinatrii edetas, acidum hydrochloridum 25 per centum, aqua ad iniectabile q.s. ad solutionem pro 0.4 ml corresp. natrium 0.92 mg. - multiple sklerose - biotechnologika

Sviss - ítalska - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - ofatumumabum - soluzione iniettabile in penna preriempita - ofatumumabum 20 mg, argininum, natrii acetas trihydricus, natrii chloridum, polysorbatum 80, dinatrii edetas, acidum hydrochloridum 25 per centum, aqua ad iniectabile q.s. ad solutionem pro 0.4 ml corresp. natrium 0.92 mg. - multiple sklerose - biotechnologika

Sviss - ítalska - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - fingolimodum - capsule - fingolimodum 0.5 mg ut fingolimodi hydrochloridum, amylum pregelificatum, natrii laurilsulfas corresp. natrium 0.045 mg, kapselhülle: e 171, e 172 (flavum), gelatina, drucktinte: lacca, propylenglycolum, ammoniae solutio concentrata, e 172 (nigrum), kalii hydroxidum, pro capsula. - multiple sklerose - synthetika

Sviss - ítalska - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - fingolimodum - capsule rigide - fingolimodum 0.5 mg ut fingolimodi hydrochloridum, calcii hydrogenophosphas dihydricus, glycinum, silica colloidalis anhydrica, magnesii stearas, kapselhülle: e 171, gelatina, e 172 (rubrum), e 172 (flavum), drucktinte: lacca, propylenglycolum, e 172 (nigrum), kalii hydroxidum, pro capsula. - multiple sklerose - synthetika

Sviss - ítalska - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - fingolimodum - capsule - fingolimodum 0,5 mg per fingolimodi hydrochloridum, mannitolum, magnesio stearas, kapselhülle: e 172 (giallo), e 171, gelatina, drucktinte: lacca, alcol isopropylicus, alcol butylicus, propylenglycolum, acqua purificata, ammoniae soluzione del 28 per cento, kalii hydroxidum, e 172 (nero), e 172 (giallo), e 171, dimeticonum per una piccola scatola. - multiple sklerose - synthetika

Sviss - ítalska - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - fingolimodum - capsule - fingolimodum 0.25 mg ut fingolimodi hydrochloridum, mannitolum, hydroxypropylcellulosum, hydroxypropylbetadexum, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (flavum), drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammoniae solutio 28 per centum pro capsula. - multiple sklerose - synthetika

Sviss - ítalska - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - ozanimodum - capsule rigide - ozanimodum 0.23 mg ut ozanimodi hydrochloridum 0.25 mg, cellulosum microcristallinum, silica colloidalis anhydrica, carmellosum natricum conexum corresp. natrium max. 0.187 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172, drucktinte: lacca, propylenglycolum, kalii hydroxidum, e 172, pro capsula. - multiple sklerose, colitis ulcerosa - synthetika